Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing

Full text
Author(s):
Show less -
Mendrone-Junior, Alfredo [1, 2] ; Dinardo, Carla Luana [1, 3] ; Ferreira, Suzete Cleuza [1] ; Nishya, Anna [1] ; Salles, Nanci Alves [1] ; de Almeida Neto, Cesar [1] ; Hamasaki, Debora Toshei [1] ; Facincani, Tila [1] ; de Oliveira Alves, Lucas Bassolli [4] ; Machado, Rafael Rahal Guaragna [5] ; Araujo, Danielle Bastos [5] ; Durigon, Edison Luiz [5, 6] ; Rocha, Vanderson [1, 2, 4] ; Sabino, Ester Cerdeira [3]
Total Authors: 14
Affiliation:
[1] Undacao Pro Sangue Hemoctr Sao Paulo, Sao Paulo - Brazil
[2] Univ Sao Paulo, Med Sch, Lab Med Invest Pathogenesis & Directed Therapy On, HCFMUSP, Sao Paulo - Brazil
[3] FMUSP, Inst Med Trop, Sao Paulo - Brazil
[4] Serv Hematol Hemoterapia & Terapia Celular HCFMUS, Sao Paulo - Brazil
[5] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, Sao Paulo - Brazil
[6] Sci Platform Pasteur USP, Sao Paulo - Brazil
Total Affiliations: 6
Document type: Journal article
Source: Transfusion; v. 61, n. 4 JAN 2021.
Web of Science Citations: 0
Abstract

Background The efficacy of convalescent plasma (CP), an alternative for the treatment of COVID-19, depends on high titers of neutralizing antibodies (nAbs), but assays for quantifying nAbs are not widely available. Our goal was to develop a strategy to predict high titers of nAbs based on the results of anti-SARS-CoV-2 immunoassays and the clinical characteristics of CP donors. Study Design and Methods A total of 214 CP donors were enrolled and tested for the presence of anti-SARS-CoV-2 antibodies (IgG) using two commercial immunoassays: EUROIMMUN (ELISA) and Abbott (Chemiluminescence). Quantification of nAbs was performed using the Cytopathic Effect-based Virus Neutralization test. Three criteria for identifying donors with nAbs >= 1:160 were tested: - C1: Curve ROC; - C2: Conditional decision tree considering only the IA results and - C3: Conditional decision tree including both the IA results and the clinical variables. Results The performance of the immunoassays was similar referring to both S/CO and predictive value for identifying nAbs titers >= 1:160. Regarding the studied criteria for identifying CP donors with high nAbs titers: (a) C1 showed 76.1% accuracy if S/CO = 4.65, (b) C2 presented 76.1% accuracy if S/CO >= 4.57 and (c) C3 had 71.6% accuracy if S/CO was >= 4.57 or if S/CO was between 2.68-4.57 and the last COVID-19-related symptoms were recent (within 19 days). Conclusion SARS-CoV-2 IgG immunoassays (S/CO) can be used to predict high anti-SARS-CoV-2 nAbs titers. This study has proposed different criteria for identifying donors with >= 1:160 nAbs titers, all with high efficacy. (AU)

FAPESP's process: 20/06409-1 - Evaluation of humoral immune response and inflammatory response in patients with confirmed diagnosis of COVID-19 at Hospital Sírio Libanês and correlation with disease severity
Grantee:Edison Luiz Durigon
Support type: Regular Research Grants
FAPESP's process: 16/20045-7 - Antigen discovery and development of serological diagnostic methods and vaccine approaches against the Zika Virus (ZIKV)
Grantee:Luis Carlos de Souza Ferreira
Support type: Research Projects - Thematic Grants
FAPESP's process: 17/24769-2 - Zika virus in postpartum women and newborns: seroepidemiology and molecular characterization
Grantee:Rafael Rahal Guaragna Machado
Support type: Scholarships in Brazil - Doctorate (Direct)